CSF2 and B-cell non-Hodgkin lymphoma: CAR with modified binding affinities of scFv component [109], reduced cytokine secreting potential: CD19; B cell lymphoma [110] and genetically modified CAR: CRISPR/CAS9 mediated granulocyte macrophage colony-stimulating factor (GM-CSF) knockout CAR are being evaluated and have shown promising results in preclinical and early phase clinical trials.